
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares are trading higher by 10.5% at $151.00 after the company reported better-than-expected fourth-quarter EPS and sales results.
Jazz Pharmaceuticals reported quarterly earnings of $4.21 per share which beat the analyst consensus estimate of $3.63. Jazz Pharmaceuticals also reported quarterly sales of $896.73 million which beat the analyst consensus estimate of $865.88 million by 4%. This is a 35% increase over sales of $665.52 million the same period last year.